If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksETX.L Regulatory News (ETX)

  • There is currently no data for ETX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

16 Feb 2022 11:47

RNS Number : 8892B
e-Therapeutics plc
16 February 2022
 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00B2823H99

Issuer Name

E-THERAPEUTICS PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of financial instruments

3. Details of person subject to the notification obligation

Name

Spreadex LTD

City of registered office (if applicable)

St. Albans

Country of registered office (if applicable)

United Kingdom

4. Details of the shareholder

Full name of shareholder(s) if different from the person(s) subject to the notification obligation, above

 

City of registered office (if applicable)

 

Country of registered office (if applicable)

 

5. Date on which the threshold was crossed or reached

14-Feb-2022

6. Date on which Issuer notified

16-Feb-2022

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

0.000000

< 3%

Position of previous notification (if applicable)

0.000000

4.005700

4.005700

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

Sub Total 8.A

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

CFD/Spreadbet

5168858

1.004500

Sub Total 8.B1

5168858

1.004500%

8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

Sub Total 8.B2

9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

Matthew Allen01727895011

12. Date of Completion

16-Feb-2022

13. Place Of Completion

UK

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLEAFAKFLSAEFA
Date   Source Headline
11th Feb 20207:00 amRNSBoard Changes and Placing
13th Jan 202012:58 pmRNSCorrection - Director/PDMR Shareholding
2nd Jan 20203:28 pmRNSDirector/PDMR Shareholding
8th Nov 201910:54 amRNSHolding(s) in Company
29th Oct 20194:10 pmRNSHolding(s) in Company
28th Oct 20192:36 pmRNSHolding(s) in Company
28th Oct 201912:05 pmRNSHolding(s) in Company
28th Oct 20198:00 amRNSHolding(s) in Company
7th Oct 20197:00 amRNSHalf-year Report
17th Sep 20194:41 pmRNSHolding(s) in Company
4th Sep 20192:05 pmRNSSecond Price Monitoring Extn
4th Sep 20192:00 pmRNSPrice Monitoring Extension
4th Sep 201911:05 amRNSSecond Price Monitoring Extn
4th Sep 201911:00 amRNSPrice Monitoring Extension
23rd Aug 201911:21 amRNSHolding(s) in Company
22nd Aug 201911:42 amRNSHolding(s) in Company
13th Aug 20197:00 amRNSe-therapeutics to work with top pharma company
1st Aug 20197:00 amRNSExtends Research Collaboration with Novo Nordisk
15th Jul 20192:06 pmRNSSecond Price Monitoring Extn
15th Jul 20192:00 pmRNSPrice Monitoring Extension
2nd Jul 20197:00 amRNSDirector/PDMR Shareholding
28th Jun 20192:06 pmRNSSecond Price Monitoring Extn
28th Jun 20192:00 pmRNSPrice Monitoring Extension
27th Jun 20193:17 pmRNSHolding(s) in Company
26th Jun 20194:41 pmRNSHolding(s) in Company
6th Jun 20193:58 pmRNSHolding(s) in Company
30th Apr 201911:21 amRNSResult of AGM
2nd Apr 20197:00 amRNSDirector/PDMR Shareholding
29th Mar 201910:00 amRNSDirector/PDMR Shareholding
20th Mar 201911:05 amRNSSecond Price Monitoring Extn
20th Mar 201911:00 amRNSPrice Monitoring Extension
14th Mar 201912:39 pmEQSEdison issues outlook on Jersey Electricity (JEL)
8th Mar 201910:30 amRNSNotice of Annual General Meeting and Annual Report
5th Mar 20193:51 pmEQSEdison issues update on e-Therapeutics (ETX)
5th Mar 20197:00 amRNSFull Year Results
20th Feb 20197:00 amRNSNotification of Full Year Results Date
3rd Jan 20199:00 amRNSDirector/PDMR Shareholding
12th Dec 20181:01 pmEQSEdison Investment Research Limited: Edison issues outlook on e-Therapeutics (ETX)
10th Dec 20187:00 amRNSResearch Collaboration Agreement with Novo Nordisk
6th Dec 201810:36 amEQSEdison Investment Research Limited: Edison issues update on e-Therapeutics (ETX)
6th Dec 20187:00 amRNSE-therapeutics and C4X Collaboration
29th Nov 20187:00 amRNSDrug Discovery Innovation Programme Presentation
12th Nov 201811:30 amRNSe-therapeutics to present at BioCentury Summit
5th Nov 20187:00 amRNSHolding(s) in Company
8th Oct 201810:42 amEQSEdison issues update on e-Therapeutics (ETX)
4th Oct 20187:00 amRNSInterim Results for six months ended 31 July 2018
17th Sep 201811:30 amRNSNotice of Interim Results
9th Aug 20187:00 amRNSDirector Shareholding
7th Aug 20187:00 amRNSDirector/PDMR Shareholding
3rd Jul 20182:08 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.